GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

Home・Aandelen Lijst・Novo Nordisk A-S (Class B)

Novo Nordisk A-S (Class B)

Gesloten

288.45 1.26

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

286.85

Max

289.85

Belangrijke statistieken
By Trading Economics
Inkomsten	22B 49B
Verkoop	18B 97B
K/W Sectorgemiddelde	10.403 49.701
EPS	10.91
Dividendrendement	4.09
Winstmarge	50.15
Werknemers	67,900
EBITDA	32B 69B

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+9.53% upside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	4.09% 2.39%
Volgende Winsten	5 aug 2026
Volgende Ex Dividend datum	13 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	8.6B 1.3T
Vorige openingsprijs	287.19
Vorige sluitingsprijs	288.45

Novo Nordisk A-S (Class B) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 mei 2026, 15:48 UTC

Acquisities, Fusies, Overnames

Novo Nordisk to Sell Parkinson's Cell Therapy to Startup Cellular Intelligence

6 mei 2026, 07:30 UTC

Winsten

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill -- Update

6 mei 2026, 06:19 UTC

Winsten

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill

18 mei 2026, 13:10 UTC

Marktinformatie

Winsten

Novo Nordisk Report Shows Bright Spots Amid Price Pressure -- Market Talk

12 mei 2026, 12:05 UTC

Populaire aandelen

Stocks to Watch: GameStop, Venture Global, Wendy's, Hims & Hers -- WSJ

12 mei 2026, 10:51 UTC

Populaire aandelen

Stocks to Watch: GameStop, Venture Global, Hims & Hers, GoPro -- WSJ

12 mei 2026, 09:42 UTC

Winsten

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

12 mei 2026, 09:08 UTC

Populaire aandelen

Stocks to Watch: Venture Global, Hims & Hers, GoPro -- WSJ

11 mei 2026, 20:30 UTC

Winsten

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

7 mei 2026, 09:30 UTC

Winsten

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

6 mei 2026, 12:36 UTC

Winsten

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

6 mei 2026, 10:53 UTC

Populaire aandelen

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

6 mei 2026, 10:12 UTC

Winsten

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

6 mei 2026, 09:58 UTC

Winsten

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

6 mei 2026, 09:35 UTC

Populaire aandelen

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

6 mei 2026, 08:13 UTC

Marktinformatie

Winsten

Novo Nordisk Guidance Tweak Unlikely to Drive Upgrades -- Market Talk

6 mei 2026, 07:43 UTC

Marktinformatie

Winsten

Novo Nordisk Consensus Earnings Expectations Likely to Rise -- Market Talk

6 mei 2026, 07:00 UTC

Winsten

Novo Nordisk Shares Rise 5.5% After 1Q Results

6 mei 2026, 06:34 UTC

Winsten

Novo Nordisk Execs Were Speaking on Media Call After 1Q Earnings

6 mei 2026, 06:26 UTC

Winsten

Novo Nordisk CFO: Branded GLP-1 Market is Expanding

6 mei 2026, 06:26 UTC

Winsten

Novo Nordisk CFO: Data Indicates There is a Lower Share of Compounders in The Market

6 mei 2026, 06:24 UTC

Winsten

Novo Nordisk CFO: Believe We've Found a Sweet Spot in Terms of Pricing With Wegovy Pill

6 mei 2026, 06:20 UTC

Winsten

Novo Nordisk CEO: Very Excited By What We See With Wegovy Pill

6 mei 2026, 06:19 UTC

Winsten

Novo Nordisk CFO: So Far Competitor's Pill Hasn't Impacted Wegovy Pill Trajectory

6 mei 2026, 06:13 UTC

Winsten

Novo Nordisk CEO: Continue To Try and Improve Our Pipeline Internally and Externally

6 mei 2026, 06:13 UTC

Winsten

Novo Nordisk CEO: Seen Continued Interest In Our Pill Despite Competitor Entering Market

6 mei 2026, 06:12 UTC

Winsten

Novo Nordisk CFO: Impact From Higher Oil Prices is Immaterial to Co

6 mei 2026, 05:43 UTC

Winsten

Novo Nordisk: Total Wegovy Pill Prescriptions Since Launch Now Exceed 2M

6 mei 2026, 05:42 UTC

Winsten

Novo Nordisk: Total Prescriptions For Wegovy Pill in 1Q Reached Around 1.3M

6 mei 2026, 05:40 UTC

Winsten

Novo Nordisk: First Wegovy Pill Launches Outside U.S. Expected During 2H26

Peer Vergelijking

Prijswijziging

Novo Nordisk A-S (Class B) Prognose

Koersdoel

By TipRanks

9.53% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 1,162.73 DKK 9.53%

Hoogste 1,550 DKK

Laagste 720 DKK

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Novo Nordisk A-S (Class B) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Novo Nordisk A-S (Class B) - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.